The U.S. Food and Drug Administration (FDA) is pushing for a shift away from animal testing in early-stage drug development, encouraging companies to adopt more modern and human-relevant methods.

In its latest draft guidance, the regulator has asked drugmakers to consider alternative approaches, known as New Approach Methodologies (NAMs), while submitting safety data for experimental drugs. These include computer-based simulations, lab-grown human cells, and advanced models that mimic human organs.

The move reflects growing concern that traditional animal testing does not always predict how a drug will behave in humans. Many treatments that show positive results in animals fail during human trials, raising questions about the reliability of such models.

By promoting these newer methods, the FDA aims to make drug development faster, more cost-effective, and ethically sustainable. Officials believe that technologies like AI-driven modelling and organ-on-chip systems can generate more accurate data while also reducing dependence on animal studies.

This is not a one-off step. The guidance builds on the FDA’s broader roadmap to gradually phase out animal testing requirements in certain areas of drug development. Earlier initiatives had already encouraged reduced use of non-human primates in specific studies, particularly for monoclonal antibodies.

The push is also supported by increased investment in human-based research, including funding from agencies like the National Institutes of Health. Together, these efforts signal a wider shift in the scientific and regulatory ecosystem toward more predictive and humane testing models.

Overall, the FDA’s move highlights a significant transition in how new drugs are evaluated. As alternative technologies evolve, animal testing may gradually become less central to early-stage research, reshaping the future of pharmaceutical development.